Press release article from our research archive:

Herceptin Receives Positive Opinion in Europe for Early Use in HER2-Positive Breast Cancer.

BASEL, Switzerland, April 28 /PRNewswire/ --

- Important Step Towards Broad Access of Herceptin for Women With Aggressive Form of Breast Cancer

Roche today announced that the European Union's Committee for Human Medicinal Products (CHMP) has issued a positive recommendation for the use of Herceptin following surgery and standard chemotherapy as adjuvant treatment of early-stage HER2-positive breast cancer. HER2-positive breast cancer, which affects approximately 20% - 30%[i] of women with breast cancer, demands special and immediate attention because the tumours are fast-growing and there is a higher likelihood of relapse.

The CHMP's decision is based on ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!